Final study reports for Dengue fever vaccine- Sanofi Pasteur.
Sanofi Pasteur, the vaccines division of Sanofi announced that the final landmark phase III efficacy study of its Dengue vaccine candidate in Latin America successfully achieved its primary clinical endpoint. Results showed an overall significant reduction of 60.8 percent of Dengue disease cases in children and adolescents 9-16 years old after a three-dose vaccination schedule.95 percent CIs overall efficacy [52.0 percent, 68.0 percent]; Efficacy per serotype (ST1 50.3%, ST2 42.3%, ST3 74.0%, ST4 77.7%); 95 percent CIs reduction of the risk of hospitalization [64.7 percent, 89.5 percent] Importantly, efficacy was observed against each of the four Dengue serotypes.
Additional observations of the results showed a clinically important reduction by 80.3 percent in the risk of hospitalization due to Dengue during the study. The results also showed in the study population an efficacy against dengue haemorrhagic fever (DHF), the severe form of dengue, which is consistent with the results released from Sanofi�s phase III dengue study in Asia. Lastly, the results suggest better protection in case of prior exposure to Dengue.
Related news and insights
Anavex Life Sciences Corp. announced positive topline results from its Phase IIb/III ANAVEX2-73-AD-004 clinical trial of oral ANAVEX2 73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD).
Vaxxinity announced today that its next generation UB 612 COVID-19 vaccine, when administered as a single heterologous booster dose, elicited strong neutralizing antibodies against SARS-CoV-2 when compared head-to-head to three globally authorized platform vaccines administered as homologous boosters, confirming success in meeting the primary and key secondary immunogenicity endpoints of its pivotal global Phase III trial.